Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

322 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Innocenti F, Jiang C, Sibley AB, Denning S, Etheridge AS, Watson D, Niedzwiecki D, Hatch AJ, Hurwitz HI, Nixon AB, Furukawa Y, Kubo M, Crona DJ, Kindler HL, McLeod HL, Ratain MJ, Owzar K. Innocenti F, et al. Among authors: niedzwiecki d. Pharmacogenet Genomics. 2019 Aug;29(6):123-131. doi: 10.1097/FPC.0000000000000375. Pharmacogenet Genomics. 2019. PMID: 30889042 Free PMC article. Clinical Trial.
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM, Mayer RJ. Posner MC, et al. Among authors: niedzwiecki d. Ann Surg Oncol. 2008 Jan;15(1):158-64. doi: 10.1245/s10434-007-9654-7. Epub 2007 Nov 16. Ann Surg Oncol. 2008. PMID: 18008108 Clinical Trial.
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Kulke MH, et al. Among authors: niedzwiecki d. J Clin Oncol. 2009 Nov 20;27(33):5506-12. doi: 10.1200/JCO.2009.22.1309. Epub 2009 Oct 26. J Clin Oncol. 2009. PMID: 19858396 Free PMC article. Clinical Trial.
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Kindler HL, et al. Among authors: niedzwiecki d. J Clin Oncol. 2010 Aug 1;28(22):3617-22. doi: 10.1200/JCO.2010.28.1386. Epub 2010 Jul 6. J Clin Oncol. 2010. PMID: 20606091 Free PMC article. Clinical Trial.
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM; Cancer and Leukemia Group B. O'Reilly EM, et al. Among authors: niedzwiecki d. Oncologist. 2010;15(12):1310-9. doi: 10.1634/theoncologist.2010-0152. Epub 2010 Dec 10. Oncologist. 2010. PMID: 21148613 Free PMC article. Clinical Trial.
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).
Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D; Cancer and Leukemia Group B. Romanus D, et al. Among authors: niedzwiecki d. J Pain Symptom Manage. 2012 Feb;43(2):205-17. doi: 10.1016/j.jpainsymman.2011.09.001. Epub 2011 Nov 21. J Pain Symptom Manage. 2012. PMID: 22104618 Free PMC article. Clinical Trial.
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance.
Jeon J, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Atienza D, Messino M, Kindler H, Venook A, Fuchs CS, Meyerhardt JA. Jeon J, et al. Among authors: niedzwiecki d. Clin Colorectal Cancer. 2013 Dec;12(4):233-8. doi: 10.1016/j.clcc.2013.06.005. Epub 2013 Sep 10. Clin Colorectal Cancer. 2013. PMID: 24035029 Free PMC article.
Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance).
Fuchs MA, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA. Fuchs MA, et al. Among authors: niedzwiecki d. PLoS One. 2014 Jun 17;9(6):e99816. doi: 10.1371/journal.pone.0099816. eCollection 2014. PLoS One. 2014. PMID: 24937507 Free PMC article.
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).
Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O'Reilly EM, Fuchs C, Innocenti F, Venook AP; Alliance for Clinical Trials in Oncology. Van Loon K, et al. Among authors: niedzwiecki d. J Natl Cancer Inst. 2014 Aug 6;106(8):dju185. doi: 10.1093/jnci/dju185. Print 2014 Aug. J Natl Cancer Inst. 2014. PMID: 25099612 Free PMC article.
322 results